Outset Medical (OM) Q2 2026 Earnings Call Transcript
Outset Medical (OM) reported Q2 2026 revenue of $31.6 million, up 1% year over year and 14% sequentially. Console revenue was $9.5 million, up 6% YoY, while product revenue fell 5% to $21.9 million. Non-GAAP gross margin was 42.2%. Cash and investments were $151 million. Full-year revenue guidance is $125 million to $130 million.
How this was made
The 30-second read
Why it matters
Traders can update valuation and expectations using the reiterated 2026 revenue range, margin trajectory, cash burn target, and the newly highlighted $40M HCA refresh agreement that extends contracted backlog through 2028.
Market read
The call centers on guidance reiteration plus a concrete contracted refresh-cycle milestone, which can shift near-term expectations for recurring console revenue and margin durability.
What to watch
Recurring revenue declined 2% YoY and consumables revenue fell 12%, which could pressure longer-term utilization and gross margin sustainability despite the service margin expansion.
Background
Outset Medical is a dialysis technology company with console, consumables, and service revenue streams; it is targeting margin expansion and recurring console cycles.
Ticker impact
Outset Medical reported Q2 2026 results and reiterated full-year revenue guidance of $125M to $130M, plus a $40M HCA refresh agreement.
Moderately positive bias for the next session and into guidance revisions, assuming the market focuses on the refresh-cycle backlog and margin expansion.
The article includes multiple concrete, decision-relevant disclosures: Q2 revenue/margin performance, full-year guidance, and a $40M, three-year HCA refresh agreement through 2028. However, it is a transcript recap and the excerpt is truncated, limiting visibility into any additional Q&A-driven risks.
Market effects
Reinforces the dialysis equipment model where console refresh cycles can create recurring service and consumables demand.
No clear regional read-through beyond US hospital adoption mentioned (Texas system, top health systems).
Limited, as the disclosures are US provider and console fleet focused.
Counterpoint
Capital sales variability remains a stated challenge, so the refresh win may not fully offset lumpiness in console placements and recurring revenue.
Key entities
- companyOutset Medical, Inc.
Reported Q2 2026 financials, reiterated FY2026 revenue guidance, and highlighted a $40M HCA refresh agreement through 2028.
- customer/partnerHCA Healthcare
Signed a $40M refresh agreement with Outset for console fleet updates through 2028.
- executiveLeslie Trigg
CEO who discussed margin progress, refresh-cycle opportunity, and capital sales variability.
- executiveRenee Gaeta
CFO who presented financial metrics including margins, cash use, and guidance.
